Impact of Therapeutic Changes on Renal Graft Survival With Posttransplant Glomerulonephritis
| Autor: | Alvaro Pacheco-Silva, Niels Olsen Saraiva Câmara, Gianna Mastroianni-Kirsztajn, Marcello Franco, Lúcio R. Requião-Moura, K.S. Ozaki, Grace Tamara Moscoso-Solorzano |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Urinary system medicine.medical_treatment Gastroenterology chemistry.chemical_compound Glomerulonephritis Postoperative Complications Internal medicine Living Donors medicine Humans Transplantation Creatinine Proteinuria business.industry Graft Survival Immunosuppression Middle Aged medicine.disease Kidney Transplantation Surgery chemistry Methylprednisolone Concomitant Female medicine.symptom business Immunosuppressive Agents Kidney disease medicine.drug |
| Zdroj: | Transplantation Proceedings. 39:453-456 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2007.01.037 |
| Popis: | Introduction Posttransplant glomerulonephritis (GN) is the third cause of graft loss after 1 year of transplant follow-up; few approaches have been efficient in reversing this outcome. The aim of this study was to evaluate whether the modification of the immunosuppressive therapy for treating posttransplant GN had an impact on allograft survival. Patients and Methods Forty-nine patients who underwent renal transplantation and developed posttransplant GN were divided into two groups: group 1, 22 patients with modified immunosuppressive treatment (72.3%, pulse of methylprednisolone; 13.6%, high-dose oral corticosteroid), and group 2, where it was maintained. Additionally, the impact of the concomitant use of drugs that promote the renin–angiotensin–aldosterone system blockade (RAASB) was analyzed in terms of graft survival. Results We established the diagnosis of GN at 17.9 months (range, 0.57 to 153.4) after transplantation, when serum creatinine (Cr) was 2.2 mg/dL (range, 0.8 to 12.5) and proteinuria 3.2 g/L (range, 0.2 to 24.2). Graft survivals at 1 and 3 years after diagnosis were 69.2% and 52.9%, respectively. The patients of group 1 showed a lower prevalence of graft loss (27.2% versus 48.1%, P = .40) and better survival at the end of 1 year (73.2% versus 60.4%) and 3 years (62.5% versus 38.0%, P = .26), but the differences were not significant. RAASB showed a positive impact on survival at the end of 3 years in both groups: for group 1, 83.8% with RAASB, 41.4% without RAASB; and for group 2, 75% with RAASB and 14.8% without RAASB ( P Conclusion Although treatment of posttransplant GN with modification of immunosuppression seemed to improve graft survival in the first 3 years after diagnosis, RAASB improved this effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect